Stockholders' Equity | 8. Stockholders’ Equity The Company is authorized to issue 700,000,000 shares of $0.001 par value common stock and 50,000,000 shares of $0.001 par value preferred stock. As of December 31, 2020, 59,183,076 shares of common stock are outstanding, and no shares of preferred stock are outstanding. Common Stock Transactions During October 2020 in connection with the Reorganization, each share of common stock was exchanged for approximately 0.39406 shares of the Company’s common stock (subject to rounding to eliminate fractional shares). In October 2020, the Company completed an IPO of 21,430,000 common stock shares, and in November 2020, the Company issued an additional 3,214,500 common stock shares through the underwriters’ over-allotment option, each at $7.00 per share raising an aggregate of $172,512. Underwriting fees incurred in conjunction with the IPO and issuance of additional common stock are recorded as a reduction to Paid-in Capital. In October 2020, the Company also issued 47,061 common stock shares to executive officers for deferred salary compensation incurred in 2020 and converted the outstanding convertible notes into 2,712,003 common stock shares, each at $7.00 per share. During May 2019, the Company issued 2,083,334 common stock shares at $12.00 per share raising $25,000 in a private placement. During June 2019, the Company issued 38,822 common stock shares at $12.00 per share raising $465 in a private placement. During July 2019, the Company issued 1,250,000 common stock shares at $12.00 per share raising $15,000 in a private placement. Equity Compensation Plan The Company has a Long-Term Incentive Plan under which options and shares of the Company’s common stock are authorized for grant or issuance as compensation to eligible employees, consultants, and members of the Board of Directors. Awards under the plan include stock options, stock appreciation rights, stock awards, deferred stock units, and performance awards. Stock options and deferred stock units have been granted by the Company in different periods. As of December 31, 2020, approximately 9.4 million shares of common stock were available for grant under the plan. Stock-based compensation expense for the years ended December 31, 2020 and 2019 was $4,368 and $3,007, respectively. Stock Option Transactions The Company’s stock options have a contractual term of 10 years and entitle the holder to purchase one share of the Company’s common stock. The options granted to the Company's employees and LGJV personnel prior to 2020 have a requisite service period of four years and vest in equal annual installments. Starting in 2020, the options granted to the Company's employees and LGJV personnel have a requisite service period of three years. The options granted to non‑employee directors prior to 2020 have a requisite service period of one year and vest in equal monthly installments. The options granted to non-employee directors in January 2020 have a requisite service period of one and a half years and vest in monthly installments. On December 31, 2020, there was $9,377 of unrecognized stock‑based compensation expense which is expected to be recognized over a weighted-average period of 2.2 years. The following table summarizes the respective vesting start dates and number of options granted to employees and directors in 2020 and 2019: Recipient Options Granted Vesting Start Date Grant Date Employees 508,500 December 14, 2018 May 3, 2019 Directors 93,000 December 14, 2018 May 3, 2019 Employees 416,000 January 20, 2020 January 20, 2020 Directors 197,666 January 20, 2020 January 20, 2020 Employees 164,000 January 20, 2020 January 30, 2020 Directors 20,667 March 1, 2020 March 1, 2020 Employees 12,000 July 31, 2020 July 31, 2020 Employees 1,127,500 October 27, 2020 October 27, 2020 The following assumptions were used to compute the fair value of the options granted using the Black-Scholes option valuation model: Grant Date May 2019 Jan. 2020 Mar. 2020 Jul. 2020 Oct. 2020 Risk-free interest rate % % % % % Dividend yield — — — — — Estimated volatility % % % % % Expected option life 6 years 6 years 6 years 6 years 6 years Post-Reorganization, the weighted‑average grant date fair value per share was $5.65 and $7.00 for the years ended December 31, 2020 and 2019, respectively. The following assumptions were used to compute the fair value of the LGJV Personnel options using the Black-Scholes option valuation model as of December 31, 2020 and 2019: December 31, 2020 2019 Risk-free interest rate % % Dividend yield — — Estimated volatility % 63.60 % Expected option life 6 years 6 years The Company's estimated volatility computation was based on the historical volatility of a group of peer companies' common stock over the expected option life and included both exploration stage and development stage companies. The peer information was used because the Company was not publicly traded and therefore did not have the market trading history required to calculate a meaningful volatility factor. The computation of the expected option life was determined based on a reasonable expectation of the option life prior to being exercised or forfeited. The risk-free interest rate assumption was based on the U.S. Treasury constant maturity yield at the date of the grant over the expected life of the option. No dividends are expected to be paid. The following tables summarize the stock option activity for the years ended December 31, 2020: Weighted‑Average Aggregate Weighted‑Average Exercise Intrinsic Remaining Employee & Director Options Shares Price Value Life (Years) Outstanding at December 31, 2019 3,551,186 $ Granted 1,937,833 $ Exercised — $ — Forfeited (77,089) $ Outstanding at December 31, 2020 5,411,930 $ $ 17,516 Vested at December 31, 2020 3,251,211 $ $ 9,292 Weighted‑Average Aggregate Weighted‑Average Exercise Intrinsic Remaining LGJV Personnel Options Shares Price Value Life (Years) Outstanding at December 31, 2019 54,595 $ Granted — $ — Exercised — $ — Forfeited (10,919) $ Outstanding at December 31, 2020 43,676 $ $ 253 Vested at December 31, 2020 43,676 $ $ 253 Deferred Stock Unit Transactions Deferred stock units (“DSUs”) are awarded to directors at the discretion of the Board of Directors. The DSUs are fully vested on the grant date and each DSU entitles the holder to receive one share of the Company’s common stock upon departure from the Company. The fair value of DSUs are equal to the fair value of the Company’s common stock on the grant date. On January 20, 2020, the Company granted 5,103 DSUs to Directors as compensation for director fees from October 2019 through December 2019. At December 31, 2020 and 2019, there were 182,714 and 177,611 DSUs outstanding, respectively. |